Evgin, Laura
Huff, Amanda L.
Wongthida, Phonphimon
Thompson, Jill
Kottke, Tim
Tonne, Jason
Schuelke, Matthew http://orcid.org/0000-0002-8399-1537
Ayasoufi, Katayoun
Driscoll, Christopher B.
Shim, Kevin G.
Reynolds, Pierce
Monie, Dileep D. http://orcid.org/0000-0001-6782-2613
Johnson, Aaron J.
Coffey, Matt
Young, Sarah L.
Archer, Gary
Sampson, John
Pulido, Jose
Perez, Luis Sanchez
Vile, Richard http://orcid.org/0000-0003-2192-9372
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA175386, R01 CA108961)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 10 October 2019
Accepted: 29 May 2020
First Online: 24 June 2020
Competing interests
: L.E., L.S.P., R.G.V. have intellectual property related to the use of IFNAR disruption in CAR T cells for combination with oncolytic viruses. M. Coffey is President and CEO at Oncolytics Biotech Inc and has ownership interest (including stock, patents, etc.) in Oncolytics Biotech Inc.